The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity - PubMed (original) (raw)
Comparative Study
. 2004 Mar;34(3):752-761.
doi: 10.1002/eji.200324427.
Affiliations
- PMID: 14991605
- DOI: 10.1002/eji.200324427
Free article
Comparative Study
The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity
Joseph Lustgarten et al. Eur J Immunol. 2004 Mar.
Free article
Abstract
The majority of tumor-associated antigens are aberrantly expressed or overexpressed normal gene products. Therefore, mechanisms responsible for self tolerance dampen immune responses against these antigens. To evaluate the effect that tolerance has on the immune responses against tumor antigens, we characterized the CD8+ T cell responses in neu mice. T cell responses against the A2.1/neu p369-377 and p773-782 peptides were evaluated in neu mice that were crossed with A2.1/Kb transgenic mice (A2 x neu). Tetramer binding and cytotoxic activity demonstrate that, compared to CTL from A2.1/Kb x FVB wild-type mice (A2 x FVB), CD8+ T cells from A2 x neu mice were of lower avidity for the peptides. Despite the fact that A2 x neu mice are tolerant, multiple immunizations with DC pulsed with the p369-377 or p773-782 peptides in the presence of IL-2 retarded tumor growth in A2 x neu mice, and immunizations in combination with the anti-OX40 mAb further enhanced the antitumor response. Taken together, these data indicate that low-avidity T cells for neu antigens persisting in A2 x neu mice have the capacity to develop antitumor responses as long as they are provided with efficient costimulation. These results underscore the potential role of low-avidity T cells in antitumor immunity and may offer an important component for vaccination immunotherapies.
Similar articles
- Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgström P, Lustgarten J. Cuadros C, et al. Int J Cancer. 2005 Oct 10;116(6):934-43. doi: 10.1002/ijc.21098. Int J Cancer. 2005. PMID: 15856473 - Identification of cross-reactive peptides using combinatorial libraries circumvents tolerance against Her-2/neu-immunodominant epitope.
Lustgarten J, Dominguez AL, Pinilla C. Lustgarten J, et al. J Immunol. 2006 Feb 1;176(3):1796-805. doi: 10.4049/jimmunol.176.3.1796. J Immunol. 2006. PMID: 16424210 - Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice.
Cuadros C, Dominguez AL, Frost GI, Borgstrom P, Lustgarten J. Cuadros C, et al. Cancer Res. 2003 Sep 15;63(18):5895-901. Cancer Res. 2003. PMID: 14522915 - Immunogenic HER-2/neu peptides as tumor vaccines.
Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, Papamichail M. Baxevanis CN, et al. Cancer Immunol Immunother. 2006 Jan;55(1):85-95. doi: 10.1007/s00262-005-0692-3. Epub 2005 Oct 27. Cancer Immunol Immunother. 2006. PMID: 15948002 Free PMC article. Review. - Cellular immunity to the Her-2/neu protooncogene.
Kiessling R, Wei WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K, Seliger B. Kiessling R, et al. Adv Cancer Res. 2002;85:101-44. doi: 10.1016/s0065-230x(02)85004-7. Adv Cancer Res. 2002. PMID: 12374283 Review.
Cited by
- Immunogenicity of rat-neu+ mouse mammary tumours determines the T cell-dependent therapeutic efficacy of anti-neu monoclonal antibody treatment.
Sow HS, Benonisson H, Brouwers C, Linssen MM, Camps M, Breukel C, Claassens J, van Hall T, Ossendorp F, Fransen MF, Verbeek JS. Sow HS, et al. Sci Rep. 2020 Mar 3;10(1):3933. doi: 10.1038/s41598-020-60893-8. Sci Rep. 2020. PMID: 32127568 Free PMC article. - Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses.
Quandt J, Schlude C, Bartoschek M, Will R, Cid-Arregui A, Schölch S, Reissfelder C, Weitz J, Schneider M, Wiemann S, Momburg F, Beckhove P. Quandt J, et al. Oncoimmunology. 2018 Sep 21;7(12):e1500671. doi: 10.1080/2162402X.2018.1500671. eCollection 2018. Oncoimmunology. 2018. PMID: 30524892 Free PMC article. - A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors.
Mira E, Carmona-Rodríguez L, Tardáguila M, Azcoitia I, González-Martín A, Almonacid L, Casas J, Fabriás G, Mañes S. Mira E, et al. Oncotarget. 2013 Dec;4(12):2288-301. doi: 10.18632/oncotarget.1376. Oncotarget. 2013. PMID: 24317954 Free PMC article. - Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Jain R, Rawat A, Verma B, Markiewski MM, Weidanz JA. Jain R, et al. J Natl Cancer Inst. 2013 Feb 6;105(3):202-18. doi: 10.1093/jnci/djs521. Epub 2013 Jan 8. J Natl Cancer Inst. 2013. PMID: 23300219 Free PMC article. - CCR5 in cancer immunotherapy: More than an "attractive" receptor for T cells.
González-Martín A, Mira E, Mañes S. González-Martín A, et al. Oncoimmunology. 2012 Jan 1;1(1):106-108. doi: 10.4161/onci.1.1.17995. Oncoimmunology. 2012. PMID: 22720226 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous